Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Insulin Resistance 5 Hyperglycemia 3 Polycystic Ovary Syndrome 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Oligomenorrhea 1 Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Intracranial Aneurysm 1 Hypoglycemia 1 Hyperphagia 1 Hyperinsulinism 1 Hyperandrogenism 1 Hirsutism 1 Diabetes Mellitus, Type 2 1 Diabetes Mellitus, Type 1 1 Congenital Abnormalities 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Brain Neoplasms 1

Interventions

Surveys and Questionnaires 114 Exercise 103 Blood Specimen Collection 99 Radiotherapy 67 Gemcitabine 64 Bevacizumab 57 Standard of Care 56 Cisplatin 55 Cyclophosphamide 51 Capecitabine 50 Carboplatin 49 Docetaxel 47 pembrolizumab 46 Dexamethasone 46 Paclitaxel 45 Interviews as Topic 43 Oxaliplatin 40 Magnetic Resonance Spectroscopy 39 Fluorouracil 37 Methods 36 Irinotecan 36 Therapeutics 33 Drug Therapy 33 Radiosurgery 31 Nivolumab 30 Erlotinib Hydrochloride 27 Educational Status 26 Everolimus 24 Leucovorin 23 Control Groups 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neoplasms × Insulin × Clear all

NCT07628556 2026-06-05

Antidiabetic Medications and Risk of Cancer

University of Pecs

74,799 enrolled

Diabetes Mellitus, Type 2, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡